TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: Use of a Novel Fibrin Sealant in Total Knee Arthroplasty

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2/PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Patients must be male or female of any race~* Ages 18-80 years old~* Patients must be undergoing an elective, primary knee arthroplasty performed by the principal investigator~Exclusion Criteria:~* Allergy or intolerance to the study materials~* Surgical intervention during the past month for the treatment of the painful joint or its underlying etiology~* History of previous surgeries on the affected joint including previous arthroscopy (open surgeries)~* Women that are pregnant or may become pregnant~* Patient declines to participate

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: t

Study Arms:
- Control Group (Type: NO_INTERVENTION): Control group. Will not receive the fibrin spray.
- Treatment Group--Evicel Fibrin Spray (Type: ACTIVE_COMPARATOR): Patient will receive the fibrin spray after implantation of device but before the wound is closed.~Patients will be randomized to receive spray or not and postop parameters measured.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Clinical Study of TUTI-16 in Asymptomatic HIV-1 Infected Subjects

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE1/PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males and Females~* Age ≥18 and ≤50 years at Screening~* HIV-1 seropositive~* asymptomatic and in generally good health~* no prior anti-retroviral therapy within 6 months of screening~* viral load ≥ 3,000 ≤ 100,000 HIV-1 RNA copies/mL~* CD4+ T-cell count ≥ 400/mm3.~Exclusion Criteria:~* Pregnant/nursing females~* positive for HBV or HCV~* acute Herpetic event~* any clinically significant out-of range laboratory value~* subject is unable or unwilling to discontinue during the study~* participation in another investigational drug/vaccine study within 30 days preceding the first injection of investigational agent in this study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 50 Years
- Healthy Volunteers: f

Study Arms:
- Placebo (Type: PLACEBO_COMPARATOR): None
- TUTI-16 0.03 mg (Type: EXPERIMENTAL): Subcutaneous injection on Day 0, Day 28, and Day 84
- TUTI-16 0.1 mg (Type: EXPERIMENTAL): Subcutaneous injection on Day 0, Day 28, and Day 84
- TUTI-16 0.6 mg (Type: EXPERIMENTAL): Subcutaneous injection on Day 0, Day 28, and Day 84

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Cerebral Palsy: Short-burst Interval Training

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Ambulatory children with cerebral palsy Spasticity primary movement disorder Bilateral motor impairment (Diplegia) Gross Motor Function Classification System Levels II and III~Exclusion Criteria:~* undergone orthopedic or neurosurgery less than 12 months prior injection therapies (phenol, botulinum toxin) less than 3 months prior

- Gender: ALL
- Minimum Age: 5 Years
- Maximum Age: 12 Years
- Healthy Volunteers: f

Study Arms:
- Short burst Interval Treadmill Training High Frequency (Type: EXPERIMENTAL): Participants receive short burst interval treadmill training for a total of 20 sessions. They are randomized to receive it either 5x/week for 4 weeks
- Short Burst Interval Treadmill Training Low Frequency (Type: ACTIVE_COMPARATOR): Participants receive short burst interval treadmill training for a total of 20 sessions. They are randomized to receive it either 2x/week for 10 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Personalized Treatment Algorithms for Difficult-to-treat Asthma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* History of provider-diagnosed asthma~* Meets one of the following definition for NAEPP guidelines uncontrolled moderate persistent asthma or severe persistent asthma in the past 12 months:~  * NAEPP step 3-4 with one of the following criteria in the past 12 months:~    * Two Asthma Control Test (ACT) scores \<20~   * 1 Urgent Care or Emergency Department visit or hospitalization for asthma~   * \>2 prednisone bursts~ * NAEPP step 5-6~* Current health insurance coverage at enrollment. This will be verified at V1 at the registration desk. If the family loses insurance during the study, the patient will be referred to the pulmonary social worker and financial office for assistance~* Reside at a primary home on average 5 out of 7 days a week.~* Primary home is within a 40 mile radius of Cincinnati Children's Base location or PI's discretion.~Exclusion Criteria:~* Received biologic therapy 6 months prior to enrollment~* Received systemic steroids 6 weeks prior to enrollment~* Active chronic disease apart from asthma or allergic disease~* Co-morbid lung disease~* Dependence on immunosuppressive drugs for a condition other than asthma~* Participant is pregnant~* Has a severe bleeding disorder~* Has significant developmental disability~* Share a bedroom with a currently enrolled Breath Warriors study participant

- Gender: ALL
- Minimum Age: 6 Years
- Maximum Age: 17 Years
- Healthy Volunteers: f

Study Arms:
- Personalized Treatment (Type: EXPERIMENTAL): Personalized asthma treatment plan based off of individual's asthma severity/control, personal and family medical history, history of environmental exposures, adherence, medical visits, biomarker assays, and home trigger assessment.~Study participants were prescribed recommended medications for the treatment of their asthma. These medications were prescribed through their insurance based of the of personalized treatment plan recommendation. Asthma controller medications may be increased based off of the participant's asthma control and the recommendation of the personalized plan. They would receive one of the asthma controller medications listed in the intervention.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Vedolizumab (MLN0002) in Patients With Moderate to Severe Ulcerative Colitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~Each patient must meet all of the following inclusion criteria to be enrolled in the study:~1. Diagnosis of moderately to severely active ulcerative colitis~2. Demonstrated, over the previous 5 year period, an inadequate response to, loss of response to, or intolerance at least 1 of the following agents:~   1. Immunomodulators~  2. Tumor necrosis factor-alpha (TNFα) antagonists~  3. Corticosteroids~3. May be receiving a therapeutic dose of conventional therapies for inflammatory bowel disease (IBD) as defined by the protocol~Exclusion Criteria:~1. Evidence of abdominal abscess at the initial screening visit~2. Extensive colonic resection, subtotal or total colectomy~3. Ileostomy, colostomy, or known fixed symptomatic stenosis of the intestine~4. Have received non permitted IBD therapies within either 30 or 60 days, depending on the medication, as stated in the protocol~5. Chronic hepatitis B or C infection~6. Active or latent tuberculosis

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Vedolizumab (Type: EXPERIMENTAL): In the Induction Phase participants received vedolizumab 300 mg, administered by intravenous infusion at Week 0 and Week 2 (Days 1 and 15).~In the Maintenance Phase, participants who demonstrated a clinical response at Week 6 according to protocol-specified criteria were randomized in a 1:1:1 ratio to double-blind treatment with vedolizumab administered every 4 weeks, vedolizumab administered every 8 weeks, or placebo for up to Week 50. Participants who did not demonstrate response at Week 6 of the Induction Phase continued treatment with vedolizumab, administered every 4 weeks during the Maintenance Phase.
- Placebo (Type: PLACEBO_COMPARATOR): In the Induction Phase participants received placebo intravenous infusion at Week 0 and Week 2 (Days 1 and 15). Participants continued to receive placebo during the Maintenance Phase, regardless of treatment response during Induction.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 6.0

Eligibility Criteria:
Inclusion Criteria:~* Diagnosis of chronic spontaneous urticaria for at least 6 months~* Diagnosis of chronic spontaneous urticaria refractory to standard of care at time of randomization~Exclusion Criteria:~* Clearly defined underlying etiology for chronic urticaria other than chronic spontaneous urticaria~* Evidence of parasitic infection~* Any other skin disease with chronic itching~* Previous treatment with omalizumab or QGE031~* Contraindications to or hypersensitivity to fexofenadine, loratadine, cetirizine, or epinephrine~* History of anaphylaxis~* History or current diagnosis of ECG abnormalities indicating significant risk of safety for patients participating in the study~* History of hypersensitivity to any of the study drugs or its components of similar chemical classes~* Pregnant or nursing (lactating) women~Other protocol defined inclusion/exclusion criteria may apply.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- QGE031 24 mg s.c. q4w (Type: EXPERIMENTAL): ligelizumab 24 mg injection subcutaneous every 4 weeks
- QGE031 72 mg s.c. q4w (Type: EXPERIMENTAL): ligelizumab 72 mg injection subcutaneous every 4 weeks
- QGE031 240 mg s.c. q4w (Type: EXPERIMENTAL): ligelizumab 240 mg injection subcutaneous every 4 weeks
- Omalizumab 300 mg s.c. q4w (Type: ACTIVE_COMPARATOR): omalizumab 300 mg injection subcutaneous every 4 weeks
- Placebo s.c. q4w (Type: PLACEBO_COMPARATOR): placebo injection subcutaneous every 4 weeks
- QGE031 120 mg s.c. s.d. (Type: EXPERIMENTAL): ligelizumab 120 mg injection subcutaneous single dose

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: S9628 Dexamethasone Plus Interferon Alfa in Treating Patients With Primary Systemic Amyloidosis

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Histologically diagnosed primary systemic amyloidosis based on the following:~  * Deposition of fibrillary protein with Congo red positive stain or characteristic electron microscopic appearance~ * Monoclonal light chain protein (Bence-Jones protein) in serum or urine or immunohistochemical studies~ * Evidence of tissue involvement other than carpal tunnel syndrome~ * Diagnostic histologic material available for central pathology review~    * Confirmation of tissue diagnosis at all sites of organ dysfunction encouraged~* No senile, secondary, localized, dialysis-related, or familial amyloidosis~* No known therapy-related myelodysplasia~PATIENT CHARACTERISTICS:~Age:~* Adult~Performance status:~* SWOG 0-4~Hematopoietic:~* Not specified~Hepatic:~* Not specified~Renal:~* Not specified~Cardiovascular:~* No NYHA class IV status~Other:~* No uncontrolled diabetes~* No active peptic ulcer disease~* No medical condition that precludes high-dose steroids~* No second malignancy within 5 years except:~* Adequately treated nonmelanomatous skin cancer~* In situ cervical cancer~* Adequately treated stage I/II cancer in complete remission~* Not pregnant or nursing~* Effective contraception required of fertile patients~* Blood/body fluid analyses within 14 days prior to registration~* Imaging/exams for tumor measurement within 28 days prior to registration~* Other screening exams within 42 days prior to registration~PRIOR CONCURRENT THERAPY:~Biologic therapy~* No prior interferon alfa~Chemotherapy~* Prior melphalan allowed, but recovered from effects~* At least 4 weeks since cytotoxic therapy and recovered~Endocrine therapy~* Prior prednisone allowed, but recovered from effects~* At least 4 weeks since prior glucocorticoids~* No prior dexamethasone~* No planned or concurrent dexamethasone or other therapy for primary systemic amyloidosis~Radiotherapy~* Not specified~Surgery~* Not specified

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- induction and maintenance (Type: EXPERIMENTAL): dexamethasone induction followed by alpha interferon maintenance

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study of Ixekizumab (LY2439821) in bDMARD-Naive Participants With Radiographic Axial Spondyloarthritis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Are ambulatory.~* Diagnosis of radiographic axial spondyloarthritis (rad-xSpA) with sacroiliitis defined radiographically according to the modified New York criteria.~* Participants have a history of back pain ≥3 months with age at onset \<45 years.~* In the past had an inadequate response to at least 2 non-steroidal anti-inflammatory drugs (for duration 4 weeks) or cannot tolerate NSAIDS.~* If taking NSAIDS be on a stable dose for at least 2 weeks prior to randomization.~* Have a history of prior therapy for axSpa for at least 12 weeks prior to screening.~Exclusion Criteria:~* Have total ankylosis of the spine.~* Have received any prior, or are currently receiving, treatment with biologics, tumor necrosis factor inhibitors or other immunomodulatory agents.~* Have recently received a live vaccine within 12 weeks or have had a vaccination with Bacillus Calmette-Guerin (BCG) within the past year.~* Have an ongoing or serious infection within the last 12 weeks or evidence of active tuberculosis.~* Have a compromised immune system.~* Have any other serious and/or uncontrolled diseases.~* Have either a current diagnosis or a recent history of malignant disease.~* Have had major surgery within 8 weeks of baseline, or will require surgery during the study.~* Are pregnant or breastfeeding.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Q2W Ixekizumab (Type: EXPERIMENTAL): Double Blind Period: Starting dose of 80 or 160 milligrams (mg) ixekizumab given subcutaneously (SC) at baseline followed by 80 mg ixekizumab given SC every two weeks (Q2W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W from week 16 to week 52.
- Q4W Ixekizumab (Type: EXPERIMENTAL): Double Blind Period: Starting dose of 80 or 160 mg ixekizumab given SC at baseline followed by 80 mg ixekizumab given SC every four weeks (Q4W) to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q4W from week 16 to week 52.
- Placebo (Type: PLACEBO_COMPARATOR): Double Blind Period: Placebo given SC Q2W to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 16 to week 52.
- Adalimumab (Type: ACTIVE_COMPARATOR): Double Blind Period: 40 mg Adalimumab given SC Q2W to week 14.~Extended Treatment Period: 80 mg ixekizumab given SC Q2W or Q4W from week 20 to week 52.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Dose Ranging Study of Metronidazole Vaginal Gel in the Treatment of Bacterial Vaginosis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE2
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Females at least 18 years of age~* In good general health~* Confirmed current diagnosis of bacterial vaginosis (determined at study screening)~* Negative pregnancy test (for women who are able to become pregnant)~* Must abstain from sexual intercourse throughout the first 7 days of thes study~* Must abstain from alcohol ingestion during the treatment period and for one day afterward~* Must not use intra-vaginal products for the duration of the study~Exclusion Criteria:~* Pregnant, lactating, or planning to become pregnant during the study period~* Menstruating at the time of the diagnosis or anticipate the onset of menses during the treatment phase of the study~* Had a medical event within 90 days of the visit (e.g., stroke, heart attack, etc.)~* Received specific treatments/medications /therapy within the designated time period prior to study enrollment

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1D (Type: ACTIVE_COMPARATOR): None
- 3D (Type: ACTIVE_COMPARATOR): None
- 5D (Type: ACTIVE_COMPARATOR): None
- Metronidazole (Type: ACTIVE_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy Study of Icotinb in Non-small Cell Lung Cancer (NSCLC) Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Confirmed NSCLC with Histology or cytology; advanced （IIIb/IV).~2. Must have received 1 or 2 chemotherapy (at least 1 is platin based)before, and prior chemotherapy must be completed at least 4 weeks before study enrollment; =.~Exclusion Criteria:~1. Previous usage of EGFR-TKI or antibody to EGFR: gefitinib, erlotinib, herceptin, erbitux.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Icotinib (Type: EXPERIMENTAL): 125 mg three times daily (375 mg per day) by mouth
- Gefitinib (Type: ACTIVE_COMPARATOR): 250 mg every 24 hours by mouth

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: CENTER-TBI: Collaborative European NeuroTrauma Effectiveness Research in TBI

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* Clinical diagnosis of TBI~* Clinical indication for CT scan~* Presentation within 24 hours of injury~* Informed consent obtained according to local and national requirements~Exclusion Criteria:~* Severe pre-existing neurological disorder that would confound outcome assessments

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Study Of Maraviroc In HIV Co-Infected Subjects With Hepatitis C And/Or Hepatitis B

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE4
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* HIV coinfected with HCV and/or HBV.~* Undetectable HIV-1 RNA for at least 3 months prior to the screening visit~* Treatment with current antiretroviral therapy (3-6 drugs excluding low-dose ritonavir) for at least 5 months.~Exclusion Criteria:~* Currently receiving maraviroc.~* Active opportunistic infections.~* ALT and/or AST \>5x upper limit of normal.~* Direct bilirubin \>1.5x upper limit of normal.~* Severe or decompensated liver disease.~* Liver disease unrelated to viral hepatitis infection.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- 1.0 (Type: EXPERIMENTAL): None
- 2 (Type: PLACEBO_COMPARATOR): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Intravitreal Injections by Nurses and Physicians Compared

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* referred to the eye clinic for treatment of age related macular degeneration, diabetes retinopathy or retinal vein occlusion with anti-vascular endothelium growth factor~* Ability to provide written informed consent~* ability to comply with study assessments for the full duration of the study~Exclusion Criteria:~-

- Gender: ALL
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- nurse (Type: EXPERIMENTAL): intravitreal injections with anti-VEGF agents given by a nurse
- physician (Type: ACTIVE_COMPARATOR): intravitreal injections with anti-VEGF agents given by a physician

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete